Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Gemcitabine/Oxaliplatin (GEMOX) with or
without Erlotinib (Tarceva) is effective in the treatment of unresectable, metastatic biliary
tract carcinoma.